
Sleep Apnea Devices Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.

Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The global sleep apnea devices market was valued at USD 7.3 billion in 2024. The market is expected to grow from USD 7.6 billion in 2025 to USD 15 billion in 2034, at a CAGR of 7.8% from 2025 to 2034, according to the latest report published by Global Market Insights Inc. The high market growth is due to the rising prevalence of sleep apnea and associated comorbidities, increasing need for portable, high-quality sleep apnea solutions, rising awareness of sleep apnea and sleep disorders, and surging aging population driving demand, among others.

Sleep apnea devices offer therapeutic and diagnostic treatment to address sleep-disordered breathing, mainly by maintaining airway patency and monitoring sleep. Key players are ResMed, BMC, Drive DeVilbiss, FISHER & PAYKEL, and Philips, among others, each with a variety of CPAP, BiPAP, and diagnostic systems designed for both clinical and home care applications.
The market has increased from USD 5.7 billion in 2021 and reached USD 6.8 billion in 2023, with a historic growth rate of 8.9%. This growth was primarily driven by rising awareness of sleep disorders, increasing prevalence of obstructive sleep apnea, technological advancements in diagnostic and therapeutic respiratory devices, and a growing preference for home-based sleep care solutions.
Sleep apnea is a widespread condition, with studies estimating that millions of individuals worldwide are affected by it, many of whom remain undiagnosed. For instance, the National Institutes of Health suggests that an estimated 1 billion people suffer from sleep apnea globally, with an estimated 936 million cases of obstructive sleep apnea. Demographic drivers, like an increased proportion of elderly patients with changing lifestyles and obesity, have driven the increasing incidence of sleep apnea. As education on the health consequences of untreated sleep apnea, such as cardiovascular conditions, diabetes, and stroke, rises, so does the population seeking medical treatment, which translates to increased demand for sleep apnea devices.
Additionally, the growing awareness of sleep apnea symptoms like loud snoring, daytime sleepiness, and lack of concentration has stimulated more individuals to undergo medical assessment. Improved diagnostic methods, like home sleep testing and in-lab polysomnography, have facilitated easy identification of sleep apnea cases. With increasing numbers of people getting diagnosed with the condition, the market for sleep apnea devices, such as CPAP (continuous positive airway pressure) machines, BiPAP, and other treatment and diagnostic equipment, is on the rise.
Sleep apnea devices are therapeutic and diagnostic devices intended to detect and treat sleep apnea. These devices play a crucial role in mitigating the health risks associated with untreated sleep apnea, thereby enhancing patient outcomes and quality of life.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2024 |
| Market Size in 2024 | USD 7.3 Billion |
| Market Size in 2025 | USD 7.6 Billion |
| Forecast Period 2025 - 2034 CAGR | 7.8% |
| Market Size in 2034 | USD 15 Billion |
| Key Market Trends | |
| Drivers | Impact |
| Increasing incidence of sleep apnea and related comorbidities | Drives higher diagnosis rates and expands the patient pool for treatment. |
| Growing demand for portable, high-performance sleep apnea solutions | Boosts sales of compact CPAP/BiPAP devices and travel-friendly options. |
| Surging awareness of sleep apnea and sleep disorders | Encourages early screening and adoption of home-based diagnostic tools. |
| The rising aging population is amplifying demand | Increases prevalence of sleep apnea among the elderly, fueling device usage. |
| Technological advancements | Enhance device efficiency, comfort, and remote monitoring capabilities. |
| Pitfalls & Challenges | Impact |
| Lack of adherence to sleep apnea treatment | Reduces long-term therapy effectiveness and impacts market retention. |
| Product recalls and safety concerns | Undermines consumer trust and disrupts supply chains. |
| Opportunities: | Impact |
| Expansion into emerging markets | Unlocking new revenue streams through untapped patient populations. |
| AI and digital health integration | Enabling personalized therapy and improving diagnostic accuracy. |
| Market Leaders (2024) | |
| Market Leaders |
~40% market share |
| Top Players |
Collective Market Share ~75% |
| Competitive Edge |
|
| Regional Insights | |
| Largest Market | North America |
| Fastest growing market | Asia Pacific |
| Emerging countries | India, China, Japan, Brazil, South Africa |
| Future outlook |
|
Technological advancements have significantly reshaped the market, driving innovation in both diagnostic and therapeutic solutions.

Based on the product, the sleep apnea devices market is segmented into therapeutics and diagnostics. The therapeutics segment accounted for 62.9% of the market in 2024 due to its dominant role in managing sleep apnea through CPAP, BiPAP, and oral sleep apnea devices, which are widely adopted for both clinical and home care use. The segment is expected to exceed USD 9.8 billion by 2034, growing at a CAGR of 8.2% during the forecast period.
On the other hand, the diagnostics segment held a market share of 37.1% in 2024. The growth of this segment can be attributed to increasing awareness of sleep disorders, rising demand for early and accurate diagnosis, and the adoption of home sleep testing solutions. Technological advancements in portable diagnostic devices and AI-enabled sleep monitoring have further accelerated the segment’s expansion, making sleep apnea screening more accessible and efficient.

Based on end use, the sleep apnea devices market is classified into home care settings and individuals and sleep laboratories and hospitals. The home care settings and individuals segment dominated the market with a revenue share of 56.9% in 2024 and is expected to reach USD 8.9 billion within the forecast period.

North America dominated the global market with the highest market share of 37.6% in 2024.
Europe market accounted for USD 2.2 billion in 2024.
The Asia Pacific market is anticipated to grow at the highest CAGR of 9.2% during the analysis timeframe.
The Latin America market is expected to experience robust growth over the analysis timeframe.
The Middle East and Africa (MEA) market is expected to experience notable growth over the analysis timeframe.
Leading industry players such as ResMed, BMC, Drive DeVilbiss, FISHER & PAYKEL, and Philips hold around 75% of the market share in the competitive market. These companies maintain their leading position by combining strong product lines, business collaborations with healthcare providers, regulatory clearances, and consistent product innovation.
ResMed continues to lead the global sleep apnea devices market with its robust portfolio of cloud-connected CPAP and BiPAP systems, including the widely adopted AirSense and AirMini series. The company’s strategic focus on digital health integration, through platforms like myAir and AirView, enables remote monitoring, personalized therapy, and improved patient adherence.
BMC Medical has carved out a strong position in emerging markets by offering affordable, high-quality CPAP, BiPAP, and sleep diagnostic devices. Known for its compact and travel-friendly solutions, BMC is rapidly gaining traction as a cost-effective alternative to premium brands. The company’s emphasis on accessibility, combined with its expanding global distribution network, makes it a key player in democratizing sleep therapy.
Meanwhile, other key players such as NIHON KOHDEN, Cadwell, and Teleflex are reinforcing their market presence through specialized innovations and strategic expansion.
A few of the prominent players operating in the sleep apnea devices industry include:
ResMed sets itself apart through its leadership in cloud-connected sleep therapy solutions and data-driven patient engagement. Its devices, such as the AirSense and AirMini series, are integrated with platforms like myAir and AirView, enabling real-time monitoring, personalized feedback, and remote therapy adjustments. ResMed’s commitment to digital health and AI-powered analytics supports improved adherence and long-term outcomes, while its global reach and scalable infrastructure make it a preferred choice across both clinical and homecare settings.
BMC Medical excels in delivering cost-effective, high-performance sleep apnea devices tailored for emerging markets and value-conscious consumers. Its product line includes compact CPAP and BiPAP systems with intuitive interfaces and auto-adjusting pressure capabilities. BMC’s emphasis on affordability, portability, and ease of use makes it a strong contender in regions with limited access to sleep therapy, while its expanding global distribution network reinforces its competitive positioning.
Drive DeVilbiss focuses on reliability and user-centric design in its sleep apnea solutions, offering a range of CPAP systems and accessories known for durability and simplicity. The company’s commitment to accessible sleep therapy and strong support infrastructure makes it a trusted provider in both institutional and homecare environments.
Market, By Product
Market, By End Use
The above information is provided for the following regions and countries:
Prominent players include Apnea Sciences, Asahi KASEI, BMC, Cadwell, Drive DeVilbiss, DynaFlex, Fisher & Paykel, Glidewell, Natus, Nihon Kohden, and Philips.
The therapeutics segment accounting for 62.9% of the market share, and is projected to exceed USD 9.8 billion by 2034.
The home care settings and individuals segment held a 56.9% market share, and is expected to reach USD 8.9 billion by 2034.
North America dominated the market with a 37.6% share in 2024. The U.S. market alone was valued at USD 2.5 billion in 2024, driven by advanced healthcare infrastructure and high awareness levels.
Key trends include the integration of cloud connectivity, AI-powered analytics, and remote monitoring in devices, along with a growing preference for portable solutions for home-based care.
The market size was USD 7.3 billion in 2024, driven by the rising prevalence of sleep apnea, increasing demand for portable solutions, and growing awareness of sleep disorders.
The market is expected to reach USD 15 billion by 2034, growing at a CAGR of 7.8% from 2025 to 2034, fueled by technological advancements and the aging population.
The market is expected to reach USD 7.6 billion in 2025.


